FOI_6937

Internal Reference Number: FOI_6937

Date Request Received: 28/12/2022 00:00:00

Date Request Replied To: 16/01/2023 00:00:00

This response was sent via: By Email

Request Summary: venetoclax used in treatment for AML and CLL

Request Category: Companies


Question Number 1: Please see attached questionnaire

Answer To Question 1: Please see attached documents. To accompany this answer to question 1 please also see the documents listed below: AzacitidineSC-Venetoclax.pdf CytarabineSC-Venetoclax.pdf ObinutuzumabVenetoclax-LowRisk.pdf VenetoclaxHigh.pdf VenetoclaxLow.pdf VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf VR-RituximabVenetoclax-Cycle-2-Onwards.pdf Venetoclax used in AML and CLL FOI 6937.pdf
Please see Attachments:









To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.